Larotrectinib efficacy and safety in TRK fusion cancer: An expanded clinical dataset showing consistency in an age and tumor agnostic approach

被引：0

作者：

Lassen, U. N. ^{[1
]}

Albert, C. M. ^{[2
]}

Kummar, S. ^{[3
]}

van Tilburg, C. M. ^{[4
,5
]}

Dubois, S. G. ^{[6
]}

Geoerger, B. ^{[7
]}

Mascarenhas, L. ^{[8
]}

Federman, N. ^{[9
]}

Schilder, R. J. ^{[10
]}

Doz, F. ^{[11
,12
]}

Berlin, J. D. ^{[13
]}

Oh, D-Y. ^{[14
]}

Bielack, S. S. ^{[15
]}

McDermott, R. ^{[16
]}

Tan, D. S. ^{[17
]}

Cruickshank, S. ^{[18
]}

Ku, N. C. ^{[18
]}

Cox, M. C. ^{[18
]}

Drilon, A. ^{[19
]}

Hong, D. S. ^{[20
]}

机构：

[1] Copenhagen Univ Hosp, Rigshosp, Dept Oncol, Finsen Ctr,Phase Unit 1, Copenhagen, Denmark

[2] Univ Washington, Fred Hutchinson Canc Res Ctr, Seattle Childrens Hosp, Pediat Oncol, Seattle, WA 98195 USA

[3] Stanford Univ, Stanford Canc Inst, Med Oncol, Stanford, CA 94305 USA

[4] Univ Heidelberg Hosp, Hopp Childrens Canc Ctr, NCT Heidelberg KiTZ, Pediat Oncol, Heidelberg, Germany

[5] German Canc Res Ctr, Heidelberg, Germany

[6] Dana Farber Boston Childrens Canc & Blood Disorde, Pediat Oncol, Boston, MA USA

[7] Inst Gustave Roussy, Dept Pediat & Adolescent Oncol, Villejuif, France

[8] Univ Southern Calif, Keck Sch Med, Childrens Hosp Los Angeles, Oncol, Los Angeles, CA 90033 USA

[9] Univ Calif Los Angeles, Pediat Oncol, Los Angeles, CA USA

[10] Thomas Jefferson Univ, Med Oncol, Philadelphia, PA 19107 USA

[11] Inst Curie, Pediat Oncol, Paris, France

[12] Univ Paris 05, Paris, France

[13] Vanderbilt Ingram Canc Ctr, Med, Nashville, TN USA

[14] Seoul Natl Univ Hosp, Med Oncol, Seoul, South Korea

[15] Klinikum Stuttgart, Pediat Oncol, Olgahosp, Stuttgart, Germany

[16] AMNCH Adelaide & Meath Hosp, Med Oncol, Dublin, Ireland

[17] Natl Canc Ctr, Med Oncol, Singapore, Singapore

[18] Loxo Oncol, Clin Dev, San Francisco, CA USA

[19] Mem Sloan Kettering Canc Ctr, Med Oncol, 1275 York Ave, New York, NY 10021 USA

[20] Univ Texas MD Anderson Canc Ctr, Med Oncol, Houston, TX 77030 USA

来源：

ANNALS OF ONCOLOGY | 2018年 / 29卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

409O

引用

页码：133 / 133

页数：1

共 50 条

[1] Larotrectinib efficacy and safety in TRK fusion cancer: An expanded clinical dataset showing consistency in an age and tumor agnostic approach
Tan, D. S. W.
Lassen, U. N.
Albert, C. M.
Kummar, S.
van Tilburg, C.
Dubois, S. G.
Geoerger, B.
Mascarenhas, L.
Federman, N.
Basu-Mallick, A.
Doz, F.
Berlin, J. D.
Oh, D-Y.
Bielack, S.
McDermott, R.
Cruickshank, S.
Ku, N. C.
Cox, M. C.
Drilon, A.
Hong, D. S.
ANNALS OF ONCOLOGY, 2018, 29
[2] Larotrectinib efficacy and safety in TRK fusion cancer: An expanded clinical dataset showing consistency in an age and tumor agnostic approach
Blattmann, C.
Albert, C. M.
Kummar, S.
van Tilburg, C. M.
Dubois, S. G.
Geoerger, B.
Mascarenhas, L.
Federman, N.
Schilder, R. J.
Doz, F.
Berlin, J. D.
Oh, D. -Y.
Bielack, S. S.
McDermott, R.
Tan, D. S.
Cruickshank, S.
Ku, N. C.
Cox, M. C.
Drilon, A.
Hong, D. S.
Lassen, U. N.
ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 : 27 - 27
[3] Larotrectinib Demonstrates Durable Efficacy and Safety in an Expanded Dataset of Pediatric Patients with TRK Fusion Cancer
Koga, Yuhki
PEDIATRIC BLOOD & CANCER, 2021, 68
[4] Larotrectinib Demonstrates Durable Efficacy and Safety in an Expanded Dataset Of Pediatric Patients With TRK Fusion Cancer
Mascarenhas, L.
Albert, C.
Pappo, A.
Geoerger, B.
Doz, F.
Federman, N.
Nagasubramanian, R.
Bielack, S.
Dubois, S.
Morgenstern, D.
Schulte, J.
Shukla, N.
Reeves, J.
De La Cuesta, E.
Dima, L.
Childs, B.
Laetsch, T.
Van Tilburg, C. M.
PEDIATRIC BLOOD & CANCER, 2020, 67 : S51 - S51
[5] EFFICACY AND SAFETY OF LAROTRECTINIB IN PEDIATRIC PATIENTS WITH TROPOMYOSIN RECEPTOR KINASE (TRK) FUSION-POSITIVE CANCER: AN EXPANDED DATASET
Koga, Yuhki
PEDIATRIC BLOOD & CANCER, 2022, 69
[6] Efficacy and safety of larotrectinib in pediatric patients with tropomyosin receptor kinase (TRK) fusion-positive cancer: An expanded dataset.
Mascarenhas, Leo
van Tilburg, Cornelis Martinus
Zwaan, Francois Doz C. Michel
Albert, Catherine M.
Blattman, Claudia
Geoerger, Birgit
DuBois, Steven G.
Federman, Noah
Nagasubramanian, Ramamoorthy
Pappo, Alberto S.
Watt, Tanya Carens
Norenberg, Ricarda
Fellous, Marc Mardoche
De la Cuesta, Esther A.
Laetsch, Theodore Willis
Xu, Rui-Hua
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[7] Long-term efficacy and safety of larotrectinib in an integrated dataset of patients with TRK fusion cancer
Leyvraz, S.
Hong, D. S.
Shen, L.
van Tilburg, C. M.
Tan, D. S. W.
Kummar, S.
Lin, J. J.
Doz, F.
McDermott, R.
Albert, C. M.
Berlin, J.
Bielack, S.
Lassen, U. N.
Tahara, M.
Norenberg, R.
Shurshalina, A.
Fellous, M.
Nogai, H.
Xu, R.
Laetsch, T. W.
Drilon, A.
ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 13 - 13
[8] Efficacy and safety of larotrectinib in patients with TRK fusion breast cancer
Rosen, Ezra Y.
Italiano, Antoine
Juric, Dejan
Reeves, John A.
Dima, Laura
Brega, Nicoletta
Drilon, Alexander
CANCER RESEARCH, 2021, 81 (04)
[9] Efficacy and safety of larotrectinib in patients with TRK fusion gastrointestinal cancer
Qi, Changsong
Shen, Lin
Andre, Thierry
Chung, Hyun Cheol
Cannon, Timothy L.
Garralda, Elena
Italiano, Antoine
Rieke, Damian T.
Liu, Tianshu
Burcoveanu, Domnita-Ileana
Neu, Natascha
Mussi, Chiara E.
Xu, Rui-Hua
Hong, David S.
Drilon, Alexander
Berlin, Jordan
EUROPEAN JOURNAL OF CANCER, 2025, 220
[10] Efficacy and safety of larotrectinib in patients with TRK fusion gastrointestinal cancer
Berlin, Jordan
Hong, David S.
Deeken, John F.
Boni, Valentina
Oh, Do-Youn
Patel, Jyoti D.
Nanda, Shivani
Brega, Nicoletta
Childs, Barrett H.
Hyman, David Michael
Drilon, Alexander E.
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)

← 1 2 3 4 5 →